Shukra Pharmaceuticals (524632) Q2 24/25 earnings summary

Executive summary

• Board approved unaudited financial results for Q2 and H1 FY2024-25 on 14 Nov 2024.

• Audit Committee reviewed related party transactions for H1 FY2024-25.

Financial highlights

• Q2 FY2024-25 revenue from operations: ₹2,463.83 lakh, up from ₹873.32 lakh in Q2 FY2023-24.

• Net profit for Q2 FY2024-25: ₹48.53 lakh, compared to ₹102.42 lakh in Q2 FY2023-24.

• H1 FY2024-25 net profit: ₹470.93 lakh, up from ₹512.95 lakh in H1 FY2023-24.

• Basic and diluted EPS for Q2 FY2024-25: ₹0.11, down from ₹0.25 in Q2 FY2023-24.

Outlook and guidance

• Statutory auditors issued an unqualified review report for Q2 FY2024-25.